{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T12:35:40Z","timestamp":1786710940184,"version":"build-2736575974"},"reference-count":21,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Dacarbazine is generally well-tolerated, apart from its hematologic toxicities; however, rare and life-threatening anaphylactic reactions have been reported. We aimed to describe a rare case of anaphylactic reaction to dacarbazine following a previously tolerated first dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Report<\/jats:title>\n                    <jats:p>We report a case of a 69-year-old male patient with classical Hodgkin lymphoma, who was planned for nivolumab, doxorubicin, vinblastine, and dacarbazine (N\u2009+\u2009AVD) combination, day 1 and 15 every 28 days. The patient received day 1 of cycle#1, without any complications. On day 15, the patient developed a severe anaphylactic reaction 5\u2005min after the start of dacarbazine infusion. The reaction was manifested by hypoxia, shivering, itching, and laryngeal edema.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management &amp; Outcome<\/jats:title>\n                    <jats:p>Patient required immediate interruption of dacarbazine infusion and received 10\u2005mg of intravenous chlorphenamine and 200\u2005mg of intravenous hydrocortisone initially with no improvement. Hypoxia and laryngeal edema improved following the administration of 0.3\u2005mg intramuscular epinephrine. The patient was transferred to the intensive care unit for close monitoring due to increased risk of biphasic anaphylactic reaction, in which symptoms can recur after initial resolution. Oxygen saturation improved from 82% to 90\u201393%, and the patient remained hemodynamically stable without complications. Dacarbazine was discontinued. Patient continued nivolumab, doxorubicin, and vinblastine (N\u2009+\u2009AV) for five cycles, and achieved complete metabolic response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This case highlights that anaphylactic reaction to dacarbazine may occur despite prior tolerance to the first dose. Physicians should suspect reaction during subsequent infusions of dacarbazine, even when initial cycle is tolerated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552261477104","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T14:56:15Z","timestamp":1786460175000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Anaphylactic reaction to the second dose of dacarbazine following initial exposure in patient with hodgkin lymphoma"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4068-549X","authenticated-orcid":false,"given":"Nour","family":"Faqeer","sequence":"first","affiliation":[{"name":"King Hussein Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6055-1371","authenticated-orcid":false,"given":"Naheel","family":"Said","sequence":"additional","affiliation":[{"name":"King Hussein Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5184-9445","authenticated-orcid":false,"given":"Tasnim","family":"Quran","sequence":"additional","affiliation":[{"name":"King Hussein Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1161-9138","authenticated-orcid":false,"given":"Khalid","family":"Halahleh","sequence":"additional","affiliation":[{"name":"King Hussein Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70341-3"},{"key":"e_1_3_3_3_2","volume-title":"UpToDate","author":"Lexicomp","unstructured":"Lexicomp. Dacarbazine: Drug information. In: Post TW (eds) UpToDate. UpToDate. (accessed 14 February 2026)."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00518-z"},{"key":"e_1_3_3_5_2","volume-title":"Dacarbazine for injection, USP [package insert]","year":"2022","unstructured":"Dacarbazine for injection, USP [package insert]. Fresenius Kabi USA, 2022."},{"key":"e_1_3_3_6_2","first-page":"18","article-title":"Anaphylactic shock due to dacarbazine (NSC 45388)","volume":"142","author":"Abhyankar S","year":"1988","unstructured":"Abhyankar S, Rao SP, Pollio L, et al. Anaphylactic shock due to dacarbazine (NSC 45388). Am J Dis Child 1988; 142: 18.","journal-title":"Am J Dis Child"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.02.013"},{"key":"e_1_3_3_8_2","first-page":"14","article-title":"Epidemiology, mechanisms, and diagnosis of drug-induced anaphylaxis","volume":"8","author":"Monta\u00f1ez MI","unstructured":"Monta\u00f1ez MI, Mayorga C, Bogas G, et al. Epidemiology, mechanisms, and diagnosis of drug-induced anaphylaxis. Front Immunol 2017 May 29; 8: 14.","journal-title":"Front Immunol"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405888"},{"key":"e_1_3_3_10_2","first-page":"1041","article-title":"Inferring ADR causality by predicting the Naranjo Score from Clinical Notes","volume":"2020","author":"Rawat BPS","year":"2021","unstructured":"Rawat BPS, Jagannatha A, Liu F, et al. Inferring ADR causality by predicting the Naranjo Score from Clinical Notes. AMIA Annu Symp Proc 2021; 2020: 1041\u20131049.","journal-title":"AMIA Annu Symp Proc"},{"key":"e_1_3_3_11_2","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. National Cancer Institute; 2017 https:\/\/dctd.cancer.gov\/research\/ctep-trials\/trial-development (accessed 14 February 2026)."},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mbm.2024.100041"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.4065\/84.3.268"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.04.029"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2022-0073"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.221319"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.resuscitation.2021.04.010"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)61217-3"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0151-9638(06)70868-7"},{"key":"e_1_3_3_20_2","first-page":"33304","article-title":"Successful desensitization to dacarbazine using pretreatment with omalizumab","volume":"42","author":"Arruti N","year":"2022","unstructured":"Arruti N, Mart\u00ednez S, Navarro JA, et al. Successful desensitization to dacarbazine using pretreatment with omalizumab. BJSTR 2022; 42: 33304\u20138.","journal-title":"BJSTR"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2019.05.007"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2020.04.017"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261477104","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552261477104","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261477104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:55:02Z","timestamp":1786708502000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552261477104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":21,"alternative-id":["10.1177\/10781552261477104"],"URL":"https:\/\/doi.org\/10.1177\/10781552261477104","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"article-number":"10781552261477104"}}